CTOs on the Move

Turning Point Therapeutics

www.tptherapeutics.com

 
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Ed Gemo
SVP/CIO Profile

Funding

Turning Point Therapeutics raised $45M on 05/23/2017
Turning Point Therapeutics raised $80M on 10/19/2018
Turning Point Therapeutics raised $202.5M on 09/16/2019
Turning Point Therapeutics raised $373.8M on 05/18/2020

Similar Companies

MindLinc: Duke University BHI

MindLinc: Duke University BHI is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmagreen Biotech

harmagreen is a company focused on BIOTECH SCIENCES utilizing proprietary technologies and formulations in its state of the art CANNABIS BOTANY CENTER

Bamboo Therapeutics

Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.

EndGenitor Technologies

EndGenitor Technologies is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Southwest Foundation For Biomedical Research

Southwest Foundation For Biomedical Research is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.